Voya Investment Management LLC Acquires 45,527 Shares of Dyne Therapeutics, Inc. $DYN

Voya Investment Management LLC raised its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 85.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 98,701 shares of the company’s stock after acquiring an additional 45,527 shares during the quarter. Voya Investment Management LLC’s holdings in Dyne Therapeutics were worth $1,249,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Squarepoint Ops LLC increased its holdings in Dyne Therapeutics by 334.3% in the 2nd quarter. Squarepoint Ops LLC now owns 181,740 shares of the company’s stock worth $1,730,000 after purchasing an additional 139,896 shares in the last quarter. Thrivent Financial for Lutherans bought a new position in Dyne Therapeutics during the second quarter worth $420,000. Caxton Associates LLP lifted its holdings in Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after buying an additional 1,627 shares during the period. Tower Research Capital LLC TRC grew its stake in Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after purchasing an additional 7,697 shares during the period. Finally, Wasatch Advisors LP boosted its holdings in shares of Dyne Therapeutics by 9.2% during the 2nd quarter. Wasatch Advisors LP now owns 557,937 shares of the company’s stock worth $5,312,000 after buying an additional 46,889 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Robert W. Baird set a $30.00 price target on shares of Dyne Therapeutics in a research note on Monday, December 8th. Cowen restated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Chardan Capital restated a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a report on Tuesday, December 9th. Stifel Nicolaus increased their target price on shares of Dyne Therapeutics from $36.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, November 14th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $38.47.

Dyne Therapeutics Stock Down 2.0%

DYN opened at $19.20 on Wednesday. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $26.22. The company has a market cap of $2.74 billion, a PE ratio of -5.25 and a beta of 1.30. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. The company has a 50 day moving average of $20.27 and a 200 day moving average of $14.81.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.05. On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.